STOCK TITAN

Medicus Pharma Ltd SEC Filings

MDCX Nasdaq

Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing Medicus Pharma’s SEC disclosures can feel like decoding lab notes. Clinical endpoints, dose-escalation tables and financing covenants pack the company’s annual report—yet each detail can shift the valuation of this oncology-focused biotech overnight. If you have ever asked, “How do I get Medicus Pharma SEC filings explained simply?” you already know the challenge.

Stock Titan turns those dense documents into clarity. Our AI delivers line-by-line context so understanding Medicus Pharma SEC documents with AI becomes second nature. Need the Medicus Pharma annual report 10-K simplified or to monitor a sudden Medicus Pharma 8-K material events explained? It’s here, refreshed the instant EDGAR posts. Key tools include:

  • Real-time alerts for every Medicus Pharma Form 4 insider transactions real-time
  • Concise takeaways from each Medicus Pharma quarterly earnings report 10-Q filing
  • AI-powered summaries that surface trial milestones, R&D spend and funding rounds
  • Downloadable tables covering Medicus Pharma executive stock transactions Form 4

Whether you’re tracking basal-cell carcinoma trial progress or assessing dilution risk, our platform connects the dots. Investors use it to spot buying patterns in Medicus Pharma insider trading Form 4 transactions, compare cash burn across quarters with our Medicus Pharma earnings report filing analysis, or review the Medicus Pharma proxy statement executive compensation before casting votes. No more hunting through PDFs—just precise, AI-driven insight when it matters.

Rhea-AI Summary

Medicus Pharma filed a prospectus supplement to its Form S-1 covering up to 3,710,000 common shares. The supplement attaches a Current Report on Form 8-K.

The 8-K details recent sales of 1,088,048 common shares to Yorkville under the Standby Equity Purchase Agreement, for approximate aggregate consideration of $2,526,364, across multiple issuances from September 8 to October 16, 2025. The company states it has used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville.

Medicus Pharma’s common shares trade on Nasdaq as MDCX; the last reported sales price was $2.41 on October 16, 2025. The company is an emerging growth company under SEC rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
-
Rhea-AI Summary

Medicus Pharma filed a prospectus supplement covering 2,260,000 common shares issuable upon the exercise of warrants. The company’s common shares and the public warrants (exercise price $4.64, expiring November 15, 2029) trade on Nasdaq as MDCX and MDCXW. On October 16, 2025, the last reported prices were $2.41 for the shares and $0.90 for the warrants.

Attached, a Current Report details recent sales under a Standby Equity Purchase Agreement with Yorkville. Between September 8 and October 16, 2025, the company sold 1,088,048 common shares to Yorkville for aggregate consideration of $2,526,364, in transactions exempt from registration under Section 4(a)(2). The company used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
-
Rhea-AI Summary

Medicus Pharma Ltd. filed a prospectus supplement updating its S-1 to cover 1,115,500 common shares issuable upon the exercise of warrants. The supplement incorporates a new Form 8-K.

The company also reported under the SEPA with Yorkville that it sold 1,088,048 common shares across multiple dates for approximately $2,526,364 in aggregate consideration, and used part of the net proceeds to prepay a portion of a debenture with Yorkville. The common shares and public warrants trade on Nasdaq as MDCX and MDCXW; on October 16, 2025, last reported prices were $2.41 and $0.90, respectively. The public warrants have a $4.64 exercise price and expire on November 15, 2029.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) reported unregistered sales of 1,088,048 common shares for approximately $2,526,364 in aggregate consideration under its Standby Equity Purchase Agreement (SEPA) with Yorkville. The sales occurred between September 8 and October 16, 2025, at prices ranging from $1.7961 to $2.7698 per share.

The company stated it has used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville. The shares were issued in reliance on Section 4(a)(2) of the Securities Act. The SEPA permits additional share purchases by Yorkville from time to time, subject to its conditions and limitations, and Yorkville may resell purchased shares pursuant to an effective registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.56%
Tags
registration
-
Rhea-AI Summary

Medicus Pharma, Inc. (MDCX) filed an S-1 registration including a prospectus structure and partial financial schedules. The filing shows multiple equity issuances during 2024–2025: common shares and warrants were issued under a Regulation A offering with issuance costs of $483,020, and a later equity financing with net offering costs of $809,606. The company records repeated net loss and comprehensive loss for successive periods and reports stock-based compensation expense and share issuances upon warrant exercises. Financing activities include proceeds from common shares and warrants, debentures and convertible notes, with related issuance costs and non-cash adjustments. The cash flow section lists net cash used in operating activities and net cash provided by financing activities, and the balance sheet excerpts reference money market funds and debentures measured at fair value. The filing also discloses operating lease right-of-use assets and liabilities, valuation inputs for warrants/options, and certain redactions under Regulation S-K.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.56%
Tags
registration
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
current report
-
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Patrick J. Mahaffy, a director of Medicus Pharma Ltd. (MDCX), reports beneficial ownership of 35,435 common shares and a stock option for 25,000 common shares exercisable through 08/29/2030 at an exercise price of $1.94. The option vests in equal quarterly installments over the 12 months following 08/29/2025. The Form 3 was signed by an attorney-in-fact on 09/08/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.17%
Tags
insider

FAQ

What is the current stock price of Medicus Pharma (MDCX)?

The current stock price of Medicus Pharma (MDCX) is $2.38 as of October 22, 2025.

What is the market cap of Medicus Pharma (MDCX)?

The market cap of Medicus Pharma (MDCX) is approximately 51.1M.
Medicus Pharma Ltd

Nasdaq:MDCX

MDCX Rankings

MDCX Stock Data

51.07M
13.17M
35.91%
14.9%
1.87%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
Canada
W. CONSHOHOCKEN